<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693534</url>
  </required_header>
  <id_info>
    <org_study_id>Long-Antagonist-AN005</org_study_id>
    <nct_id>NCT03693534</nct_id>
  </id_info>
  <brief_title>Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Long Agonist Protocol</brief_title>
  <official_title>Clinical and Live Birth Rates After Controlled Ovarian Stimulation With the Long Antagonist Protocol Versus the Long Agonist Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assisting Nature</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assisting Nature</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective study of the evaluation of the clinical IVF (in vitro fertilization) results
      after following Long Antagonist protocol for Controlled Ovarian Stimulation (COS) versus
      following Long Agonist protocol
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective study of the clinical results in women who followed the Long Antagonist
      protocol for Controlled Ovarian Stimulation (COS) versus women who followed Long Agonist
      protocol, in an In Vitro Fertilization (IVF) try. In particular, the Clinical Pregnancy Rates
      (CPR) and Live Birth Rates (LBR) were estimated for the two groups of patients. The number of
      the formed blastocysts was also measured in each group of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Pregnancy Rate according to stimulation protocol</measure>
    <time_frame>6 weeks to 42 weeks after embryo transfer</time_frame>
    <description>Clinical Pregnancy Rate according to stimulation protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of formed blastocysts in each group of patients</measure>
    <time_frame>5 days after the OPU day</time_frame>
    <description>The number of the formed blastocysts in each group of patients according to the COS protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Live Birth Rate according to stimulation protocol</measure>
    <time_frame>6 weeks to 42 weeks after embryo transfer</time_frame>
    <description>Live Birth Rate according to stimulation protocol</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pregnancy, Ovarian</condition>
  <arm_group>
    <arm_group_label>Long Antagonist Protocol</arm_group_label>
    <description>Clinical Pregnancy Rate, Live Birth Rate and Blastulation Rate of patients who followed Long Antagonist Protocol for Controlled Ovarian Stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long Agonist Protocol</arm_group_label>
    <description>Clinical Pregnancy Rate and Live Birth Rates and Blastulation Rate of patients who followed Long Agonist Protocol for Controlled Ovarian Stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Clinical Pregnancy Rate</intervention_name>
    <description>The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS</description>
    <arm_group_label>Long Agonist Protocol</arm_group_label>
    <arm_group_label>Long Antagonist Protocol</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women 18- 39 years old who follow COS with the Long Antagonist Protocol or with Long
        Agonist Protocol
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary infertility

          -  age 18-39 years; body mass index (BMI) 18-29kg/m2;

          -  regular menstrual cycle of 26-35days,

          -  presumed to be ovulatory;

          -  early follicular- phase serum concentration of FSH within normal limits (1-12 IU/l).

        Exclusion Criteria:

          -  women with diabetes and other metabolic disease

          -  women with heart disease, QT prolongation,heart failure

          -  elevated liver enzymes, liver failure, hepatitis

          -  women with inflammatory or autoimmune disease

          -  abnormal karyotype;

          -  polycystic ovarian syndrome,

          -  endometriosis stage III/IV;

          -  history of being a 'poor responder',

          -  defined as &gt;20 days of gonadotrophin in a previous stimulation cycle, or any previous
             cancellation of a stimulation cycle due to limited follicular response, or development
             of less than 4 follicles 15 mm in a previous stimulation cycle; history of recurrent
             miscarriage; severe OHSS in a previous stimula- tion cycle or any contraindication for
             the use of gonadotrophins.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evaggelos Papanikolaou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisting Nature</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Najdecki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisting Nature</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evaggelos Papanikolaou, MD,PhD</last_name>
    <phone>00302310424294</phone>
    <email>drvagpapanikolaou@yahoo.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assisting Nature</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evaggelos Papanikolaou, MD, PhD</last_name>
      <phone>00302310424294</phone>
      <email>papanikolaou@assistingnature.gr</email>
    </contact>
    <contact_backup>
      <last_name>Robert Najdecki, MD, PhD</last_name>
      <phone>00306936646464</phone>
      <email>rnajdecki@assistingnature.gr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assisting Nature</investigator_affiliation>
    <investigator_full_name>Papanikolaou Evaggelos</investigator_full_name>
    <investigator_title>Papanikolaou Evaggelos, MD, PhD, Fertility Specialist, Scientific Director at Assisting Nature IVF Clinic</investigator_title>
  </responsible_party>
  <keyword>Long Antagonist</keyword>
  <keyword>Long agonist</keyword>
  <keyword>clinical pregnancy rate</keyword>
  <keyword>live birth rate</keyword>
  <keyword>ovarian stimulation</keyword>
  <keyword>IVF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy, Ovarian</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

